Article
Pharmacology & Pharmacy
Lihong Ding, Qinwei Chen, Kai Chen, Yuelong Jiang, Genhong Li, Qiuling Chen, Dongyu Bai, Dehong Gao, Manman Deng, Haiping Zhang, Bing Xu
Summary: Constitutively activated BCR-ABL kinase is the driver event in chronic myeloid leukemia (CML) development. Imatinib, the first BCR-ABL inhibitor, has improved clinical outcomes, but resistance occurs in 25-30% of patients. Simvastatin, a HMG-CoA reductase inhibitor, shows antitumor effects and acts as a sensitizer to kill imatinib-resistant and T315I mutated CML cells.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Oncology
Changyuan Kang, Lizhou Jia, Lei Hao, Ning Zhang, Yang Liu, Lingli Zhang
Summary: POM121 is overexpressed in gastric cancer tissues compared to normal gastric tissues and is associated with deep invasion, distant metastases, and TNM stage in gastric cancer patients. POM121 promotes proliferation, migration, and invasion of gastric cancer cells through the phosphorylation of the PI3K/AKT pathway and increased expression of MYC. These findings suggest that POM121 may serve as an independent prognostic factor for gastric cancer patients.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Dhananjaya Pal, Kendra R. Vann, Shweta Joshi, Namood E. Sahar, Guillermo A. Morales, Dalia El-Gamal, Tatiana G. Kutateladze, Donald L. Durden
Summary: The study developed a first-in-class inhibitor SRX3262 that simultaneously blocks three driver pathways of MCL and overcomes resistance. The inhibitor destabilizes c-MYC, induces apoptosis, providing a new approach to treat MCL.
Article
Immunology
Guangcan Gao, Qingfeng Xue, Jing He, Meng Wu, Yongning Jiang, Quanqing Li, Yaping Zhang, Wenyu Shi
Summary: This study reveals that IMPDH2 plays a tumor-promoting role in diffuse large B cell lymphoma, especially in double-hit lymphoma cases. Inhibition of IMPDH2 significantly suppresses DHL cell proliferation, and c-Myc regulates the activation of the PI3K/AKT/mTOR signaling pathway through IMPDH2. Moreover, IMPDH2 expression is associated with decreased T-cell infiltration and concurrent high expression of PD-L1 within the tumor microenvironment. These findings provide insights into the pathogenesis of DHL and may lead to the identification of potential therapeutic targets.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Cell Biology
Ji-Sun Lee, Michael W. Lero, Jose Mercado-Matos, Sha Zhu, Minjeong Jo, Claire E. Tocheny, Jennifer S. Morgan, Leslie M. Shaw
Summary: This study reveals that the insulin/insulin-like growth factor signaling pathway supports self-renewal of breast cancer stem cells through the activation and stabilization of MYC. This process is mediated by IRS2-PI3K signaling, which enhances MYC expression and reduces MYC degradation.
Article
Oncology
Hua Yu, Liang Chen, Xia Wang, Feng Tang, Ziyu Wan, Hao Wang, Qiqi Fu, Zhizhuang Chen, Jiageng Shi, Xuan Hu, Yisha Zuhaer, Madanyeti Aersi, Tao Liu, Huangheng Tao, Jianping Peng
Summary: This study investigated the role of STIL in bladder cancer for the first time. The researchers found that STIL is highly expressed in bladder cancer and is closely related to the cell cycle. Knocking out STIL led to a significant delay in the growth rate of bladder cancer cells and arrested the cell cycle in the G0/G1 phase. Mechanistically, STIL enhanced the PI3K/AKT/mTOR pathway, resulting in increased expression of c-myc, ultimately promoting the occurrence and progression of bladder cancer.
Review
Oncology
Priyanka Singh
Summary: This study identified 111 miRNAs that potentially target the PI3K/Akt/mTOR pathway, and selected seven miRNAs for further investigation. Except for hsa-miR-199a-3p, the other six miRNAs have been extensively studied in AML. Given the similarity between AML and CML, these miRNAs may also be advantageous for treating chemoresistance in CML.
Article
Plant Sciences
Hui-Min Zhao, Jing He, Yung-Ting Chang, Li-Yun Liu, Fan Sun, Hou-Wen Lin, Fan Yang
Summary: AP-51 has shown potential as a treatment for Burkitt's lymphoma by regulating the cell cycle, inducing apoptosis, causing mitochondrial dysfunction, and inhibiting the PI3K/AKT/mTOR signaling pathway.
JOURNAL OF NATURAL PRODUCTS
(2022)
Article
Biochemistry & Molecular Biology
Ke Hu, Bo Li, Ruye Ma, Hongfei Yi, Zhijian Xu, Yu Peng, Dandan Yu, Huiqun Wu, Taofang Cheng, Yumeng Lu, Yong Zhang, Rong Wei, Guang Yang, Xiaosong Wu, Weiliang Zhu, Jumei Shi
Summary: DLBCL is a highly heterogeneous type of non-Hodgkin lymphoma, and patients with poor outcomes from conventional treatment may benefit from novel agents like DCZ0825, which exhibited high cytotoxicity towards DLBCL cells through inducing apoptosis and cell cycle arrest. The efficacy of DCZ0825 against DLBCL involves the PI3K-AKT-mTOR/JNK pathway.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2021)
Article
Oncology
Shaoying Li, Lianqun Qiu, Jie Xu, Pei Lin, Chi Young Ok, Guilin Tang, Timothy J. McDonnell, M. James You, Mahsa Khanlari, Roberto N. Miranda, L. Jeffrey Medeiros
Summary: This study investigated the clinicopathologic and genetic features of 136 HGBL-NOS patients compared to DLBCL/HGBL-DH and DLBCL patients. The study found that HGBL-NOS patients had similar clinical features to DLBCL/HGBL-DH patients. However, their overall survival was inferior to DLBCL patients.
Article
Pharmacology & Pharmacy
Teng Wang, Jun Zou, Qiong Wu, Rui Wang, Chan-Ling Yuan, Jing Shu, Bing-Bing Zhai, Xiao-Ting Huang, Ning-Zhi Liu, Feng-Yang Hua, Xi-Cheng Wang, Wen-Jie Mei
Summary: TA25, a derivate from tanshinone IIA, shows promising inhibitory effects against the proliferation, migration, and invasion of lung cancer cells. Its inhibitory effect was confirmed through MTT assay, cell colony formation assay, xenograft lung cancer cells model, wound-healing assay, FITC-gelatin invasion assay, and binding properties of TA25 interact with c-myc G-quadruplex DNA. TA25 can induce S-phase arrest, increase ROS production, cause DNA damage, inhibit the PI3K/Akt/mTOR signal pathway, and upregulate p53 protein expression in A549 cells.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Hu-ying Tang, Jia-qi Guo, Bo-tao Sang, Jun-ning Cheng, Xiang-mei Wu
Summary: This study demonstrated that PDGFRI3 has a positive regulatory role in glucose metabolism of osteosarcoma cells, promoting aerobic glycolysis through the activation of the PI3K/AKT/mTOR/c-Myc pathway. This newly discovered role provides a novel metabolic therapeutic target for osteosarcoma.
BIOCHEMISTRY AND CELL BIOLOGY
(2022)
Article
Chemistry, Medicinal
Hamdoon A. Mohammed, Mohamed G. Ewees, Nesreen I. Mahmoud, Hussein M. Ali, Elham Amin, Mohamed S. Abdel-Bakky
Summary: Suaeda vermiculata has a significant hepatoprotective effect against NDEA-induced HCC by inhibiting the PI3K/HIF-1 alpha/c-MYC/iNOS pathway.
Article
Medicine, Research & Experimental
Zhuonan Liu, Tianshui Sun, Chiyuan Piao, Zhe Zhang, Chuize Kong
Summary: The study found that METTL13 is downregulated in ccRCC and is associated with poor prognosis; METTL13 can inhibit the growth and metastasis of ccRCC cells through multiple molecular mechanisms.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Chenming Ni, Wenyu Liu, Kailian Zheng, Shiwei Guo, Bin Song, Wei Jing, Gang Li, Bo Li, Canrong Ni, Keqing Shi, Gang Jin, Guanzhen Yu
Summary: The study discovered the presence of the MLL-AFF4 fusion gene in acute leukemia and investigated the role of AFF4 in pancreatic tumorigenesis. The results showed that overexpression of AFF4 promoted cell proliferation and cell cycle progression, while two nucleotide metabolism enzymes, HPRT1 and IMPDH2, were upregulated. The study also found that AFF4 was regulated by the PI3K/c-Myc axis and was positively correlated with c-Myc and HPRT1/IMPDH2 expression in clinical PDAC samples. These findings establish AFF4 as a potential biomarker and therapeutic target for PDAC.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Letter
Oncology
Patrizia Mondello, Salvatore Cuzzocrea, Carmela Arrigo, Vincenzo Pitini, Michael Mian, Francesco Bertoni
HEMATOLOGICAL ONCOLOGY
(2020)
Article
Oncology
Patrizia Mondello, Saber Tadros, Matt Teater, Lorena Fontan, Aaron Y. Chang, Neeraj Jain, Haopeng Yang, Shailbala Singh, Hsia-Yuan Ying, Chi-Shuen Chu, Man Chun John Ma, Eneda Toska, Stefan Alig, Matthew Durant, Elisa de Stanchina, Sreejoyee Ghosh, Anja Mottok, Loretta Nastoupil, Sattva S. Neelapu, Oliver Weigert, Giorgio Inghirami, Jose Baselga, Anas Younes, Cassian Yee, Ahmet Dogan, David A. Scheinberg, Robert G. Roeder, Ari M. Melnick, Michael R. Green
Letter
Critical Care Medicine
Aravind A. Menon, David D. Berg, Elliot J. Brea, Aaron J. Deutsch, Khameer K. Kidia, Emilia G. Thurber, Sylvie B. Polsky, Tiffany Yeh, Jonathan A. Duskin, Alison M. Holliday, Elizabeth B. Gay, Laura E. Fredenburgh
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2020)
Editorial Material
Hematology
Patrizia Mondello, Andrew D. Zelenetz
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Neurosciences
Gabriella Di Rosa, Daniela Dicanio, Antonio Gennaro Nicotera, Patrizia Mondello, Laura Cannavo, Eloisa Gitto
Review
Medicine, General & Internal
Elliott J. Brea, Bruce C. Tiu, Jean M. Connors
Summary: Cancer is a major cause of venous thromboembolism, with treatment and prevention methods requiring risk stratification based on individual factors, and direct oral anticoagulants have shown comparable efficacy and safety in treating cancer-associated VTE.
POSTGRADUATE MEDICINE
(2021)
Article
Oncology
Patrizia Mondello, Angelo Fama, Melissa C. Larson, Andrew L. Feldman, Jose C. Villasboas, Zhi-Zhang Yang, Ilia Galkin, Viktor Svelolkin, Ekaterina Postovalova, Alexander Bagaev, Pavel Ovcharov, Arina Varlamova, Sarah Huet, Bruno Tesson, Kaitlyn R. McGrath, Susan Slager, Brian K. Link, Sergei Syrbu, Anne J. Novak, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Gilles Salles, James R. Cerhan, Stephen M. Ansell
Summary: Lack of intrafollicular CD4 expression is identified as a predictor of early failure in follicular lymphoma patients, and its combination with FLIPI can improve the identification of high-risk patients.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Sabela Bobillo, Erel Joffe, David Sermer, Patrizia Mondello, Paola Ghione, Philip C. Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Connie L. Batlevi, Alison Moskowitz, Ariela Noy, Collette N. Owens, M. Lia Palomba, David Straus, Gottfried von Keudell, Ahmet Dogan, Andrew D. Zelenetz, Venkatraman E. Seshan, Anas Younes
Summary: The study found that both IT-MTX and HD-MTX regimens had similar efficacy in CNS prophylaxis for patients with DLBCL, prophylaxis tended to delay rather than prevent CNS relapse, and there is a need for more effective prophylactic regimens.
BLOOD CANCER JOURNAL
(2021)
Article
Hematology
Peter G. Miller, Adam S. Sperling, Elliott J. Brea, Mark B. Leick, Geoffrey G. Fell, Max Jan, Satyen H. Gohil, Yu-Tzu Tai, Nikhil C. Munshi, Catherine J. Wu, Donna S. Neuberg, Marcela Maus, Caron Jacobson, Christopher J. Gibson, Benjamin L. Ebert
Summary: CHIP, a state in which mutations in hematopoietic cells give rise to a clonal population of cells, is common in patients receiving CAR T-cell therapy but does not impact progression-free or overall survival, especially in patients younger than 60 years old. Although it can influence response rates and cytokine release syndrome severity, it should not be a factor in determining eligibility for this potentially life-prolonging treatment.
Article
Oncology
Xinyi Tang, Zhi-Zhang Yang, Hyo Jin Kim, Theodora Anagnostou, Yue Yu, Xiaosheng Wu, Jun Chen, Jordan E. Krull, Kerstin Wenzl, Patrizia Mondello, Vaishali Bhardwaj, Junwen Wang, Anne J. Novak, Stephen M. Ansell
Summary: This study found that regulatory T-cells (Treg) are more abundant in the spleens of patients with splenic marginal zone lymphoma (SMZL) compared to reactive spleens. These Tregs can be separated into CD161(+)Treg and CD26(+)Treg subsets. CD161(+)Tregs are increased in SMZL but have dysregulated immune function. CD161(+)Tregs are associated with a favorable prognosis in SMZL, while CD26(+)Tregs are associated with a poor prognosis. Activation of the IL2/STAT5 pathway contributes to the expansion of CD26(+)Tregs and may lead to a poor clinical outcome in SMZL.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E. Waltl, Mark Winderlich, Nuwan C. Kurukulasuriya, Sumeet Ambarkhane, Georg Hess, Gilles Salles
Summary: In this retrospective study, the combination of tafasitamab and lenalidomide showed a significant improvement in overall survival compared to other treatment regimens for relapsed/refractory diffuse large B-cell lymphoma.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Patrizia Mondello, Jonas Paludo, Joseph P. Novak, Kerstin Wenzl, Zhi-Zhang Yang, Shahrzad Jalali, Jordan E. Krull, Esteban Braggio, Surendra Dasari, Michelle K. Manske, Jithma A. Abeykoon, Vivekananda Sarangi, Prashant Kapoor, Aneel Paulus, Craig B. Reeder, Sikander Ailawadhi, Asher A. Chanan-Khan, Robert A. Kyle, Morie A. Gertz, Anne J. Novak, Stephen M. Ansell
Summary: This study identified three distinct molecular clusters in IgM monoclonal gammopathy of undetermined significance (MGUS) and Waldenstro euro m macroglobulinemia (WM), which corresponded to different pathological features and clinical presentations. This finding may contribute to a biological classification of these diseases, thus providing more precise treatment options.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Wern Lynn Ng, Stephen M. Ansell, Patrizia Mondello
Summary: Current therapies for lymphoma primarily target tumor cells and pay less attention to the tumor microenvironment (TME). However, the TME plays a crucial role in the growth and survival of lymphoma. Therefore, targeting the TME has emerged as a new therapeutic strategy to comprehensively manage lymphoma and improve patient survival.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Letter
Oncology
Kimon V. Argyropoulos, Melissa Pulitzer, Francesco Maura, Abhinita Mohanty, Patrizia Mondello, Steven M. Horwitz, Patricia Myskowski, Alison Moskowitz, Ahmet Dogan, Christiane Querfeld, Franck Rapaport, Marina Siakantaris, Peter C. Louis, Natasha Galasso, Marcel R. M. van den Brink, M. Lia Palomba
BLOOD CANCER JOURNAL
(2020)
Meeting Abstract
Oncology
Patrizia Mondello, Angelo Fama, Melissa C. Larson, Andew L. Feldman, Zhi-Zhang J. Yang, Jose Caetano Villasboas, Sarah Huet, Bruno Tesson, Susan L. Slager, Brian K. Link, Sergei Syrbu, Anne Novak, Thomas Matthew Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Gilles A. Salles, James Robert Cerhan, Stephen M. Ansell
JOURNAL OF CLINICAL ONCOLOGY
(2020)